Does AFATINIB Cause Interstitial lung disease? 141 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 141 reports of Interstitial lung disease have been filed in association with AFATINIB (Gilotrif). This represents 2.3% of all adverse event reports for AFATINIB.
141
Reports of Interstitial lung disease with AFATINIB
2.3%
of all AFATINIB reports
89
Deaths
92
Hospitalizations
How Dangerous Is Interstitial lung disease From AFATINIB?
Of the 141 reports, 89 (63.1%) resulted in death, 92 (65.2%) required hospitalization, and 29 (20.6%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for AFATINIB.
What Other Side Effects Does AFATINIB Cause?
Diarrhoea (2,001)
Malignant neoplasm progression (1,622)
Rash (808)
Stomatitis (468)
Death (443)
Nausea (430)
Decreased appetite (412)
Vomiting (381)
Paronychia (344)
Dehydration (323)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which AFATINIB Alternatives Have Lower Interstitial lung disease Risk?
AFATINIB vs AFINITOR
AFATINIB vs AFLIBERCEPT
AFATINIB vs AGALSIDASE ALFA
AFATINIB vs AGALSIDASE BETA
AFATINIB vs AGOMELATINE